Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 3-4, 2003, Pages 551-562

  Yarkov, Alex V ^a   Hanger, Diane ^a   Reploge, Maria ^a   Joyce, Jeffrey N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Caudate putamen; Dopamine transporter; Parkinson's disease; S32504; S33084; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; CARBIDOPA; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LEVODOPA; S 32504; S 33084; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL MONITORING; BRAIN INJURY; CAUDATE NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FIBER; GNAWING; GROOMING; KNOCKOUT MOUSE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN FUNCTION; PUTAMEN; REARING; STEREOTYPY; WILD TYPE;

EID: 0344845081     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.09.011     Document Type: Article

References (68)

1. Arnt J. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats. Eur. J. Pharmacol. 113:1985;79-88.
2. Arnt J., Hyttel J., Perregaard J. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur. J. Pharmacol. 133:1987;137-145.
3. Beck C.H., Chow H.L., Cooper S.J. Dose-related response of male rats to apomorphine: snout contact in the open-field. Physiol. Behav. 37:1986;819-825.
4. 3 receptor function. Nat. Med. 9:2003;762-767.
5. Blanchet P.J., Konitsiotis S., Chase T.N. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 283:1997;794-799.
6. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3363-3367.
7. Bordet R., Ridray S., Schwartz J.C., Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci. 12:2000;2117-2123.
8. 3 receptor agonists. Neuropharmacology. 38:1999;1389-1396.
9. 3 knock-out and wild-type mice. Neuropharmacology. 38:1999;555-565.
10. 2 receptor agonist, S32504, in models predictive of antiparkinsonian properties. Abstr.-Soc. Neurosci. 27:2001;. [200.8].
11. Burris K.D., Pacheco M.A., Filtz T.M., Kung M.P., Kung H.F., Molinoff P.B. Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology. 12:1995;335-345.
12. Costall B., Naylor R.J. The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotyped behaviour. Eur. J. Pharmacol. 24:1973;8-24.
13. Daly S.A., Waddington J.L. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH- DPAT in relation to other "D-2-like" agonists. Neuropharmacology. 32:1993;509-510.
14. Damsma G., Bottema T., Westerink B.H., Tepper P.G., Dijkstra D., Pugsley T.A.et al. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur. J. Pharmacol. 249:1993;R9-R10.
15. 2 receptor agonist, S32504, in models predictive of antidepressant properties. Abstr. - Soc. Neurosci. 27:2001;. [665.4].
16. Depoortere R. Combined use of mutant mice and classical pharmacology to characterise receptor functions: the case of dopamine D2 and D3 receptors. Psychopharmacology (Berl). 147:1999;20-21.
17. Depoortere R., Perrault G., Sanger D.J. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl). 124:1996;231-240.
18. 2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J. Neurochem. 72:1999;148-156.
19. Gagnon C., Gomez-Mancilla B., Markstein R., Bedard P.J., Di Paolo T. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;667-676.
20. Geter-Douglass B., Katz J.L., Alling K., Acri J.B., Witkin J.M. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists. J. Pharmacol. Exp. Ther. 283:1997;7-15.
21. Gilbert D.B., Cooper S.J. 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects? Pharmacol. Biochem. Behav. 52:1995;275-280.
22. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J. Pharmacol. Exp. Ther. 275:1995;899-913.
23. Graham W.C., Clarke C.E., Boyce S., Sambrook M.A., Crossman A.R., Woodruff G.N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity: II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res. 514:1990;103-110.
24. Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J. Neurochem. 84:2003;1246-1255.
25. 2 receptor expressing neurons. Neuropsychopharmacology. 20:1999;60-80.
26. Hadjtahar A., Grondin R., Doan V.D., Gregoire L., Sokoloff P., Schwartz J.-C.et al. Behavioral effects of selective dopamine D3 receptor agonist/antagonist in primate model of Parkinson's disease. Soc. Neurosci. 25(2):1999;1598.
27. Hof P.R., Young W.G., Bloom F.E., Belichenko P.V., Celio M.R. Comparative cytoarchitectonic atlas of the C57/BL6 and 129/Sv mouse brains. 2000;Elsevier, Amsterdam (The Netherlands).
28. Jiang M., Spicher K., Boulay G., Wang Y., Birnbaumer L. Most central nervous system D2 dopamine receptors are coupled to their effectors by Go. PNAS. 98:2001;3577-3582.
29. Joyce J.N. Multiple dopamine receptors and behavior. Neurosci. Biobehav. Rev. 7:1983;227-256.
30. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine: I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system. Exp. Neurol. 113:1991;261-276.
31. 3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse. 40:2001;137-144.
32. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90:2001;231-259.
33. Joyce J.N., Marshall J.F., Bankiewicz K.S., Kopin I.J., Jacobowitz D.M. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res. 382:1986;360-364.
34. 3 receptors with degeneration of the dopamine system. NeuroReport. 11:2000;2173-2175.
35. 2 receptors. Brain Res. 955:2002;138-152.
36. Joyce J.N., Presgraves S., Renish L., Borwege S., Hagner D., Osredkar T.et al. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+)and in vivo against 1-methyl- 4-phenyl-1,2,2,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp. Neurol. 2003;. [in press].
37. 3 receptors. Neuroscience. 91:1999;911-924.
38. Khroyan T.V., Baker D.A., Neisewander J.L. Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology (Berl). 122:1995;351-357.
39. Koeltzow T.E., Xu M., Cooper D.C., Hu X.T., Tonegawa S., Wolf M.E.et al. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 18:1998;2231-2238.
40. LaHoste G.J., Marshall J.F. Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: autoradiographic evidence against the dual mechanism hypothesis. Neuroscience. 41:1991;473-481.
41. Lammers C.H., Diaz J., Schwartz J.C., Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry. 5:2000;378-388.
42. Lau Y.S., Fung Y.K. Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) on striatal dopamine receptor system. Brain Res. 369:1986;311-315.
43. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49:1997;231-252.
44. Lévesque D., Martres M.P., Diaz J., Griffon N., Lammers C.H., Sokoloff P.et al. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1719-1723.
45. 2 receptor-deficient mice. Brain Res. 792:1998;253-262.
46. Lorenc-Koci E., Wolfarth S. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. Eur. J. Pharmacol. 385:1999;39-46.
47. 3 receptors. Abstr.-Soc. Neurosci. 25:1999;1467.
48. Millan M.J., Dekeyne A., Rivet J.-M., Dubuffet T., Lavielle G., Brocco M. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293:2000;1063-1073.
49. Millan M.J., Gobert A., Newman-Tancredi A., Lejeune F., Cussac D., Rivet J.-M.et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293:2000;1048-1062.
50. Morissette M., Goulet M., Grondin R., Blanchet P., Bedard P.J., Di Paolo T.et al. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 10:1998;2565-2573.
51. Murray A.M., Weihmueller F.B., Marshall J.F., Hurtig H.I., Gottleib G.L., Joyce J.N. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann. Neurol. 37:1995;300-312.
52. Neal B.S., Joyce J.N. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development. Brain Res. Dev. Brain Res. 60:1991;105-113.
53. Neal-Beliveau B.S., Joyce J.N. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development. Dev. Psychobiol. 32:1998;313-326.
54. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience. 98:2000;263-273.
55. 2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13:1998;788-797.
56. Scarselli M., Novi F., Schallmach E., Lin R., Baragli A., Colzi A.et al. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 276:2001;30308-30314.
57. Spooren W.P., Vassout A., Waldmeier P., Gentsch C. Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity. Eur. J. Pharmacol. 353:1998;1-4.
58. Svensson K., Carlsson A., Waters N. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J. Neural Transm., Gen. Sect. 95:1994;71-74.
59. Szechtman H., Ornstein K., Teitelbaum P., Golani I. Snout contact fixation, climbing and gnawing during apomorphine stereotypy in rats from two substrains. Eur. J. Pharmacol. 80:1982;385-392.
60. Thorn L., Ashmeade T.E., Storey V.J., Routledge C., Reavill C. Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors. Neuropharmacology. 36:1997;787-792.
61. Van den Buuse M. Effects of 7-hydroxy-N,N-di-n-propylaminotetralin on behaviour and blood pressure of spontaneously hypertensive rats. Eur. J. Pharmacol. 243:1993;169-177.
62. Waters N., Lofberg L., Haadsma-Svensson S., Svensson K., Sonesson C., Carlsson A. Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J. Neural. Transm., Gen. Sect. 98:1994;39-55.
63. 2L dopamine receptors in NS20Y neuroblastoma cells. J. Neurosci. 18:1998;8692-8699.
64. 3 dopamine receptors. Psychopharmacology (Berl). 167:2003;167-173.
65. Xu M., Koeltzow T.E., Cooper D.C., Tonegawa S., White F.J. Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists. Synapse. 31:1999;210-215.
66. 3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens. J. Neurochem. 81:2002;1035-1042.
67. Zapata A., Witkin J.M., Shippenberg T.S. Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. Neuropharmacology. 41:2001;351-359.
68. o subtype of G proteins in SH-SY5Y cells. Br. J. Pharmacol. 128:1999;1181-1188.